MedTrace Logo

Effects of SHR-1222 on Vascular Inflammatory Factors in Patients With Low Bone Mass

NCT03898024 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-06-30

No results posted yet for this study

Summary

This study aims to investigate the effects of SHR-1222 on vascular inflammatory factors in patients with low bone mass.

Conditions

  • Osteoporosis, Osteopenia

Interventions

DRUG

SHR-1222

Pharmaceutical form: water injection; Route of administration: subcutaneous

DRUG

Placebo

Pharmaceutical form: water injection; Route of administration: subcutaneous

Sponsors & Collaborators

  • Second Xiangya Hospital of Central South University

    lead OTHER

Principal Investigators

  • Zhiguang Zhou, MD · Second Xiangya Hospital of Central South University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-15
Primary Completion
2020-07-27
Completion
2020-08-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03898024 on ClinicalTrials.gov